Below, I asked Chat GPT to consolidate four or five articles about Klomp.
###
Here is a consolidated, policy-focused article in your blog style—tight paragraphs, emphasis on what matters to insiders, and oriented toward “what policy watchers should actually take away.”
Chris Klomp Ascendant: What Medicare Policy Watchers Need to Know
Over the past month, a relatively obscure Medicare official has become one of the most consequential figures in U.S. health policy.
Chris Klomp, until recently head of the Center for Medicare at CMS, has been elevated to Chief Counselor and de facto #2 at HHS, with authority over operations, messaging, and coordination across a $2.6 trillion department. Multiple press accounts—from the Wall Street Journal, Politico, and Washington Post—converge on the same point: this is not a routine personnel shift. It is a White House intervention into HHS execution, with Klomp installed as the operational center of gravity.
For policy watchers, the question is not “who is Klomp?”
It is: what does his rise tell us about where Medicare policy is going?
1. This Is an Operations Coup, Not a Policy Appointment
The headlines frame Klomp as “No. 2 at HHS,” but that understates the structure.
He oversees department-wide operations and messaging
Senior counselors across CMS and FDA now report through him
He runs daily coordination across agencies
He was installed after execution failures (e.g., reversed grant cuts, FDA turbulence)
The White House diagnosis is clear:
HHS didn’t need more ideas—it needed management discipline and message control, especially ahead of midterms.
Klomp himself said the quiet part out loud: the goal is to “move faster” and ensure “uniform quality.”
Translation for insiders:
This is a centralization of authority, with Klomp acting as an internal COO across CMS, FDA, and broader HHS.
2. Why Klomp? Because of Drug Pricing—and Negotiation Style
Every source highlights the same credential: drug pricing negotiations.
Klomp:
Led negotiations tied to Most Favored Nation (MFN) policy
Earned Trump’s confidence as a “good negotiator”
Built credibility with industry (e.g., Pfizer CEO citing trust)
This is important because it signals how this White House evaluates success:
Not academic policy design
Not regulatory craftsmanship
But deal-making that produces visible wins
For policy watchers, that suggests:
Continued emphasis on negotiated outcomes over formal rulemaking
Preference for executive leverage + convening rather than statutory pathways
A bias toward policies that are legible to voters (e.g., drug prices)
3. The Real Mission: Align HHS With White House Political Priorities
The WSJ and WaPo reporting makes this explicit.
The White House:
Wants to emphasize drug pricing and affordability
Wants to de-emphasize politically toxic issues (e.g., vaccines)
Views HHS as needing tighter alignment with midterm messaging
Klomp’s role is therefore not just operational—it is political filtering:
Delaying announcements that create “headaches”
Re-centering agencies on approved narratives
Ensuring Kennedy focuses on campaign-friendly themes (e.g., food policy)
Bottom line:
Klomp is functioning as a policy gatekeeper between HHS and the White House political strategy.
4. A Non-Ideological Operator With Market Leanings
One of the more striking themes from the Washington Post profile:
Klomp was a health-tech entrepreneur, not a political figure
He had no deep prior ties to Trump or Kennedy
Colleagues describe him as pragmatic, apolitical, execution-focused
Yet his policy instincts—as seen in the Paragon interview—are consistent:
Core worldview:
Medicare pricing is not truly market-based
The system often pays for inputs, not outcomes
Government should use:
Markets where possible
Convening power where markets fail
Regulation as a last resort
Implications:
Continued push toward:
site-neutral payment
market-referenced pricing (e.g., MA, DRGs)
outcome-based models
Skepticism of:
rigid fee schedules
purely administrative pricing formulas
This places him squarely in a Paragon-adjacent but execution-driven camp:
Not ideological free-market purism
But “use markets pragmatically to fix Medicare distortions”
5. Medicare Advantage: Supportive, But With Teeth
Klomp’s posture toward Medicare Advantage is nuanced—and important.
From both press and interview:
He supports MA as central to Medicare’s future
But is willing to:
restrain payments
challenge coding practices
emphasize program integrity
Most notably, his framing of risk adjustment:
It exists to prevent adverse selection
Not to create competitive advantage
This is a subtle but important signal.
For MA stakeholders:
The administration is not anti-MA
But it is anti-“gaming MA”
Expect:
Continued scrutiny of coding intensity
Focus on linking payments to actual care
Tighter alignment of payment with outcomes
6. The “Convening” Doctrine—Quietly Central
Perhaps the most underappreciated takeaway from Klomp’s own remarks:
He repeatedly emphasizes a third tool of government:
Not legislation
Not regulation
But convening
Examples:
Prior authorization reforms driven by multi-party alignment
MFN drug pricing framed as realigning global incentives
Industry negotiations replacing rule-heavy approaches
Why this matters:
For policy watchers, it signals a shift toward:
Soft power policy tools
Voluntary alignment mechanisms
Negotiated frameworks that avoid litigation risk
In practical terms, this may mean:
Fewer sweeping NPRMs
More “announcements + deals + guidance”
Greater reliance on behavioral incentives vs mandates
7. The Management Thesis: Two Stakeholders Only
Across sources and interviews, Klomp returns to a simple principle:
CMS serves two stakeholders:
beneficiaries first, taxpayers second
That framing drives several consistent positions:
Reduce low-value spending (e.g., skin substitutes)
Shift toward primary care and prevention
Demand accountability for outcomes
Avoid unnecessary bureaucratic burden
It also explains his resistance to:
excessive micromanagement
paternalistic health policy
rules that reward navigation skill over clinical value
8. What Has Changed—And What Hasn’t
What has changed:
Klomp now has enterprise-wide authority
HHS is being run with centralized operational control
Policy is being filtered through political viability
What hasn’t changed:
The administration’s reliance on:
executive authority
negotiation over legislation
The structural challenges of Medicare:
administered pricing
unclear “true” market value
MA vs FFS tension
9. Five Takeaways for Policy Insiders
Klomp is now the operational center of HHS
Not just Medicare—everything flows through him.Execution > ideology
The White House wants results it can message, not theoretical reforms.Negotiation is the dominant policy tool
Expect more MFN-style approaches and fewer traditional rulemakings.Medicare Advantage remains safe—but scrutinized
Supportive stance, but coding and payment discipline will tighten.Market signals will creep into Medicare policy
Slowly, unevenly—but clearly a directional push.
Bottom Line
Chris Klomp is not a typical Washington health policy figure.
He is closer to a healthcare COO with policy authority.
His rise signals a shift toward:
centralized execution
negotiated policy
market-informed reforms
and tight alignment with White House political priorities
For Medicare policy watchers, the key insight is simple:
The next phase of CMS policy may be less about what rules say
and more about how incentives are engineered—and deals are struck.
